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Purpose: To report a case of non-paraneoplastic autoimmune retinopathy (npAIR)
treated with intravenous immunoglobulin (IVIG).
Case report: A 12-year-old boy presented with progressive visual field loss, nyctalopia,
and flashing for three months. He had suffered from common cold two weeks before the
onset of these symptoms. On the basis of clinical history and paraclinical findings, he
was diagnosed with npAIR, and IVIG without immunosuppressive therapy was started.
During the one-year follow-up period after the first course of IVIG, flashing disappeared
completely. Visual acuity remained 10/10, but nyctalopia did not improve. Multimodal
imaging showed no disease progression.
Conclusion: Although established retinal degenerative changes seem irreversible in
npAIR, IVIG may be a suitable choice to control the disease progression.
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INTRODUCTION
Autoimmune retinopathies (AIRs) are a heteroge-
neous group of immune-mediated degenerative
Correspondence to:
Sahba Fekri, MD. Ophthalmic Research Center, Shahid
Beheshti University of Medical Sciences. No. 23, Paidar-
fard St., Boostan 9 St., Pasdaran Ave., Tehran 16666,
Iran.
E-mail: fekri22sahba@yahoo.com
Received: 25-11-2018 Accepted: 19-06-2019
Access this article online
Website: https://knepublishing.com/index.php/JOVR
DOI: 10.18502/jovr.v15i2.6743
retinal disorders, caused by circulating antiretinal
antibodies (ARAs). They can be paraneoplastic
(pAIR) or, more commonly, non-neoplastic
(npAIR) characterized by bilateral, often
asymmetric, progressive, painless visual acuity
or visual field loss over weeks to months
with photopsias and scotomas.[1] Depending
on the cell type and antigen targeted by
ARAs, signs and symptoms may be diverse
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and overlapping. Insufficient knowledge of the
clinical course, prognosis, and treatment of AIRs
makes their management challenging. Here, we
report a case of npAIR stabilized with intravenous
immunoglobulin (IVIG).
CASE REPORT
A 12-year-old boywas referred to our clinic because
of progressive visual field loss and photopsia for
three months. He was mentally alert and per-
formed well at school. He experienced flashing
approximately two weeks after a common cold
episode. It rapidly progressed to decreased night
vision and visual field defects with difficulty walking
downstairs. There was no relevant past medical,
surgical, or drug history. The family history was
negative for autoimmune and hereditary disor-
ders. Systemic work-ups, including cell count, bio-
chemistry, and liver, kidney, and thyroid function
tests were unremarkable. The erythrocyte sedi-
mentation rate and C-reactive protein level were
within normal ranges. The patient tested nega-
tive for the antinuclear antibody, anti-neutrophil
cytoplasmic antibody, rheumatoid factor, comple-
ment components 3 and 4, total complement
activity, Venereal Disease Research Laboratory
test, anti-toxoplasma antibody, hepatitis B surface
antigen, hepatitis C virus antibody, and antihuman
immunodeficiency virus antibody. No malignancies
or rheumatologic disorders were detected. The
corrected distance visual acuity was 10/10 OU
with normal color vision and no relative afferent
pupillary defects. Slit lamp examination showed
normal anterior segment and intraocular pressure
with no inflammation. Dilated funduscopy revealed
optic disc pallor, vascular attenuation, and dif-
fuse retinal atrophy with mottling of the retinal
pigmented epithelium [Figure 1]. There were no
bone spicules or vitreous cells. Fundus autoflu-
orescence (FAF) imaging revealed perifoveal and
perivascular hyperautofluorescence [Figure 1]. Flu-
orescein angiography (FAG) revealed disc hyper-
fluorescence with mild vascular leakage [Figure 2].
Late-phase indocyanine green angiography (ICGA)
showed multiple hypocyanescent spots [Figure
2]. Optical coherence tomography (OCT) demon-
strated loss of the photoreceptor layer, disruption
of the ellipsoid zone, and thinning of the outer
nuclear layer with central sparing [Figure 3]. Full-
field electroretinography (ERG) showed severely
extinguished photopic and scotopic responses
[Figure 4]. The 24-2 Humphrey visual field con-
firmed advanced field constriction sparing fixation
[Figure 4]. The presumptive diagnosis was npAIR
based on clinical and paraclinical findings and
disease course. Serologic tests for ARAs were not
available in the country, and the patient could
not afford genetic testing. Systemic steroids (1
mg/kg) with IVIG (400 mg/kg/day for five days)
were started. His parents did not consent to
immunosuppressive therapy, therefore IVIG was
considered. Systemic steroids were tapered slowly
and discontinued after three months, but IVIG was
repeated every three months for one year. He
received four courses of the IVIG therapy. During
the 18-month follow-up period, clinical and para-
clinical features of the disease remained stable,
with no progression or improvement. Photopsia
disappeared completely. Visual acuity was 10/10
OU at all visits, and visual field defects or OCT
abnormalities did not progress [Figure 3]. After
each injection of IVIG, the patient reported an
improvement in the quality of vision lasting for two
weeks and then returning to the previous situation;
however, we could not assess these changes
objectively.
DISCUSSION
Autoimmune retinopathy is a rare immune-
mediated disorder, triggered by molecular mimicry
between retinal proteins and certain antigens that
induce immunologic sensitivity in the host.[2] Based
on the presumed nature of these antigens and
underlying etiology, AIR is categorized into pAIR,
which is related to underlying malignancies and
the similarity between tumor antigens and retinal
proteins, and npAIR, which correlates with the
similarity between presumed infectious antigens
and retinal proteins. The final outcome of all forms
is retinal degeneration. Underlying malignancies
should be ruled out before the diagnosis of npAIR
is made.[3] Signs and symptoms may be diverse
and overlapping, depending on the cell type and
antigen targeted by ARAs. Patients usually present
with acute or subacute, bilateral vision loss, visual
field defects, nyctalopia, scotomas, and photopsia.
Funduscopy may be unremarkable or reveal optic
disc pallor, vascular attenuation, retinal atrophy,
and retinal pigment epithelium mottling with
minimal or no vitritis.[1] Therefore, ancillary tests
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Figure 1. (A & B) Color fundus photograph shows optic disc pallor, vascular attenuation, and diffuse retinal atrophy with
mottling of the retinal pigmented epithelium. (C & D) Perifoveal and perivascular hyperautofluorescence is noticeable on fundus
autofluorescence imaging.
seem necessary to detect retinal degenerative
changes. Signs and symptoms of npAIR are
non-specific and may overlap with other retinal
disorders, including hereditary retinal diseases,
other degenerative retinal disorders, particularly
retinitis pigmentosa (RP), drug toxicity, and various
inflammatory or infectious etiologies.[4] Finally, to
establish the diagnosis and rule out other causes,
FAG, FAF, ICGA, visual field (VF), ERG, and OCT
may be helpful. Khanna et al reported multimodal
imaging properties of npAIR,[5] including the
characteristic pattern of diffuse or granular,
stippled hyperautofluorescence throughout the
posterior pole on FAF, peripheral visual field
constriction, amplitude reduction under scotopic
and photopic conditions on ERG, and attenuations
of the outer nuclear layer and ellipsoid zone
parafoveally on OCT. Moreover, they suggested
a diagnostic algorithm for clinical use according
to which pathognomonic findings should be
obtained from at least one objective, structural
test (SD-OCT and/or FAF) and one objective,
functional test (ERG and/or VF, if available). In our
patient, results of ancillary tests were compatible
with npAIR, and the acute onset of symptoms,
clinical course of the disease, and negative
history of hereditary retinal disorders ruled out
RP. Clinical findings of RP and npAIR overlap,
making the definitive diagnosis challenging.
Increasing knowledge of AIRs in the past years
has created doubt regarding patients who have
been followed-up for RP without any family history
of RP or typical bone spicules. In a case series,
immunosuppressive therapy was started for two
patients despite positive family history of RP
because they had classic signs of npAIR, and
visual function improved during follow-up.[6] ARAs
play a pivotal role in the pathogenesis of AIR.[2]
The detection of circulating ARAs can confirm
the diagnosis in patients with a high suspicion of
npAIR based on clinical and paraclinical findings.[7]
However, various laboratory techniques help
detect ARAs, but lack of a globally accepted
technique and poor inter-laboratory concordance
make this process challenging.[1] Moreover,
ARAs may be found in other inflammatory or
degenerative disorders, even in the normal
population. Conversely, ARAs may not be found in
many patients with AIR.[8] The detection of ARAs
in a patient can represent the following: (1) the
primary pathogenesis of retinal changes; (2) a
normal unrelated finding; (3) an epiphenomenon
resulting from the release of retinal antigens by
a pathologic process; or (4) a secondary process
worsening a pathologic progress. It is difficult
in many cases to determine which of the above
are operational.[2] Although in the consensus for
standardization of diagnostic criteria for AIR,[7] the
detection of ARAs was an essential component,
because of the aforementioned reasons, lack of
ARAs would not rule out the diagnosis. Serologic
tests for ARAs were unavailable for our patient.
The management of npAIR is also controversial.
There is no global consensus on the management
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Figure 2. (A & B) Disc hyperfluorescence is seen on fluorescein angiography. (C & D) Mild vascular leakage (almost from veins)
is more prominent at retinal mid-periphery on fluorescein angiography. (E–H) Indocyanine green angiography shows multiple
hypocyanescent spots in late stages.
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Figure 3. (A & B) Optical coherence tomography demonstrates loss of the photoreceptor layer, disruption of the ellipsoid zone,
loss of the external limiting membrane, and thinning of the outer nuclear layer with central sparing at baseline. (C & D) After one-
year follow-up and the last course of IVIG therapy, there is no change in retinal structures. (E & F) Six months after discontinuation
of IVIG therapy (18-month follow-up), stability of retinal atrophic changes is seen.
Figure 4. (A) Both photopic and scotopic responses are severely extinguished on full-field electroretinography. (B) The 24-2
Humphrey visual field depicts severe field constriction with foveal sparing.
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or prognosis of AIRs[3] because most of our knowl-
edge comes from case reports and case series.
Suggested approaches include systemic and local
corticosteroids, antimetabolites such as mycophe-
nolate mofetil, azathioprine, and T cell inhibitors
such as cyclosporine, targeted B-cell therapy such
as anti-CD20 monoclonal antibody (rituximab),
IVIG, and plasmapheresis.[1] In most cases, visual
prognosis is uncertain, but improvement in visual
field and visual acuity may occur. Therapy is not
effective in patients with widespread retinal degen-
eration. IVIG consists of human immunoglobulin G
obtained from the plasma of healthy donors. Pro-
posedmechanisms of action of IVIG in autoimmune
disorders include modulation of cellular immunity
by antibody-dependent cytotoxicity, anti-idiotypic
antibodies, blockade of immune complex binding
to receptors, blockade of cell-to-cell interactions,
induction of regulatory T cells, and downregula-
tions of T and B cell activations.[9] IVIG is usually
used as a second-line therapy in autoimmune
diseases. We used it in this patient because his
parents did not consent to immunosuppressive
therapy. Guy et al[10] reported three cases of pAIR
treated with IVIG. In one patient, visual acuity
improved dramatically within 24 h of taking the first
dose, but visual field improved two weeks later.
In the second patient, there was no improvement,
although ARA levels declined. In the third patient,
the visual field improved. Treatment was started
in early stages of disease for all patients, contrary
to our patient who had profound anatomical and
functional degenerative retinal changes at presen-
tation. A recent study showed that although the
treatment of npAIR did not produce anatomical
improvement, it ensured stability of symptoms
and prevented involvement of the second eye in
unilateral cases.[5] The disappearance of photop-
sia, subjective improvement in our patient’s vision
quality, and stabilization of the disease highlight
the possible role of IVIG in npAIR management.
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